[1]
|
Kroschinsky, F., Stölzel, F., von Bonin, S., Beutel, G., Kochanek, M., Kiehl, M., Schellongowski, P. and Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group (2017) New Drugs, New Toxicities: Severe Side Effects of Modern Targeted and Immunotherapy of Cancer and Their Management. Critical Care, 21, 89.
https://doi.org/10.1186/s13054-017-1678-1
|
[2]
|
Xu, C., Chen, Y.P., Du, X.J., Liu, J.Q., Huang, C.L., Chen, L., Zhou, G.Q., Li, W.F., Mao, Y.P., Hsu, C., Liu, Q., Lin, A.H., Tang, L.L., Sun, Y. and Ma, J. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. BMJ, 363, k4226. https://doi.org/10.1136/bmj.k4226
|
[3]
|
Khunger, M., Rakshit, S., Pasupuleti, V., Hernandez, A.V., Mazzone, P., Stevenson, J., Pennell, N.A. and Velcheti, V. (2017) Incidence of Pneumonitis with Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest, 152, 271-281.
https://doi.org/10.1016/j.chest.2017.04.177
|
[4]
|
Khoja, L., Day, D., Chen, T., Siu, L.L. and Hansen, A.R. (2017) Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systemat-ic Review. Annals of Oncology, 28, 2377-2385.
https://doi.org/10.1093/annonc/mdx286
|
[5]
|
Luo, Q., Zhang, L., Luo, C. and Jiang, M. (2019) Emerging Strategies in Cancer Therapy Combining Chemotherapy with Immunotherapy. Cancer Letters, 454, 191-203. https://doi.org/10.1016/j.canlet.2019.04.017
|
[6]
|
Shi, Y., Su, H., Song, Y., Jiang, W., Sun, X., Qian, W., Zhang, W., Gao, Y., Jin, Z., Zhou, J., Jin, C., Zou, L., Qiu, L., Li, W., Yang, J., Hou, M., Zeng, S., Zhang, Q., Hu, J., Zhou, H., Xiong, Y. and Liu, P. (2019) Safety and Activity of Sintilimab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial. The Lancet Haematology, 6, e12-e19. https://doi.org/10.1016/S2352-3026(18)30192-3
|
[7]
|
Zhou, X., Yao, Z., Bai, H., Duan, J., Wang, Z., Wang, X., Zhang, X., Xu, J., Fei, K., Zhang, Z., Tan, F., Xue, Q., Gao, S., Gao, Y., Wang, J. and He, J. (2021) Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitor-Based Combination Therapies in Clinical Trials: A Systematic Review and Meta-Analysis. The Lancet Oncology, 22, 1265-1274.
https://doi.org/10.1016/S1470-2045(21)00333-8
|
[8]
|
Varricchi, G., Marone, G., Mercurio, V., Galdiero, M.R., Bonaduce, D. and Tocchetti, C.G. (2018) Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Cur-rent Medicinal Chemistry, 25, 1327-1339.
https://doi.org/10.2174/0929867324666170407125017
|
[9]
|
Grabie, N., Lichtman, A.H. and Padera, R. (2019) T Cell Checkpoint Regulators in the Heart. Cardiovascular Research, 115, 869-877. https://doi.org/10.1093/cvr/cvz025
|
[10]
|
Michel, L., Helfrich, I., Hendgen-Cotta, U.B., Mincu, R.I., Korste, S., Mrotzek, S.M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., Umutlu, L., Coman, C., Ahrends, R., Sickmann, A., Löffek, S., Livingstone, E., Ugurel, S., Zimmer, L., Gunzer, M., Schadendorf, D., Totzeck, M. and Rassaf, T. (2022) Targeting Early Stages of Cardiotoxicity from Anti-PD1 Immune Checkpoint Inhibitor Therapy. European Heart Journal, 43, 316-329.
https://doi.org/10.1093/eurheartj/ehab430
|
[11]
|
Johnson, D.B., Pollack, M.H. and Sosman, J.A. (2016) Emerging Targeted Therapies for Melanoma. Expert Opinion on Emerging Drugs, 21, 195-207. https://doi.org/10.1080/14728214.2016.1184644
|
[12]
|
Yang, S. and Asnani, A. (2018) Cardiotoxicities Associated with Immune Checkpoint Inhibitors. Current Problems in Cancer, 42, 422-432. https://doi.org/10.1016/j.currproblcancer.2018.07.002
|
[13]
|
Ganatra, S., Parikh, R. and Neilan, T.G. (2019) Cardio-toxicity of Immune Therapy. Cardiology Clinics, 37, 385-397.
https://doi.org/10.1016/j.ccl.2019.07.008
|
[14]
|
Jain, V., Mohebtash, M., Rodrigo, M.E., Ruiz, G., Atkins, M.B. and Barac, A. (2018) Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated with Antithymocyte Glob-ulin. Journal of Immunotherapy, 41, 332-335.
https://doi.org/10.1097/CJI.0000000000000239
|
[15]
|
Harrison, M.L., Obermueller, E., Maisey, N.R., Hoare, S., Edmonds, K., Li, N.F., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles, K., Ahern, R., King, D.M., Eisen, T., Cor-ringham, R., DeWitte, M., Balkwill, F. and Gore, M. (2007) Tumor Necrosis Factor Alpha as a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. Journal of Clinical Oncology, 25, 4542-4549.
https://doi.org/10.1200/JCO.2007.11.2136
|
[16]
|
Carlos, G., Anforth, R., Chou, S., Clements, A. and Fernan-dez-Peñas, P. (2015) A Case of Bullous Pemphigoid in a Patient with Metastatic Melanoma Treated with Pembrolizumab. Melanoma Research, 25, 265-268.
https://doi.org/10.1097/CMR.0000000000000155
|
[17]
|
Chadha, S., Para, A.J. and Choi, J. (2020) Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. Current Dermatology Reports, 9, 231-243.
https://doi.org/10.1007/s13671-020-00314-1
|
[18]
|
Boutros, C., Tarhini, A., Routier, E., et al. (2016) Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nature Reviews Clinical Oncology, 13, 473-486. https://doi.org/10.1038/nrclinonc.2016.58
|
[19]
|
Sibaud, V. (2018) Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. The American Journal of Clinical Dermatology, 19, 345-361. https://doi.org/10.1007/s40257-017-0336-3
|
[20]
|
Postow, M.A., Sidlow, R. and Hellmann, M.D. (2018) Im-mune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England Journal of Medicine, 378, 158-168. https://doi.org/10.1056/NEJMra1703481
|
[21]
|
Bai, X., Wang, X., Ma, G., Song, J., Liu, X., Wu, X., Zhao, Y., Liu, X., Liu, Z., Zhang, W., Zhao, X., Zheng, Z., Jing, J. and Shi, H. (2021) Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Frontiers in Immunol-ogy, 12, Article ID: 793831.
https://doi.org/10.3389/fimmu.2021.793831
|
[22]
|
Dubin, K., Callahan, M.K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E.G. and Wolchok, J.D. (2016) Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nature Communications, 7, Ar-ticle No. 10391.
https://doi.org/10.1038/ncomms10391
|
[23]
|
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., Ribas, A. and KEYNOTE-006 Investigators (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 372, 2521-2532.
https://doi.org/10.1056/NEJMoa1503093
|
[24]
|
Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T.M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N. and Robert, C. (2017) Pembrolizumab versus Ipilimumab for Advanced Mel-anoma: Final Overall Survival Results of a Multicentre, Randomised, Open-Label Phase 3 Study (KEYNOTE-006). The Lancet, 390, 1853-1862.
https://doi.org/10.1016/S0140-6736(17)31601-X
|
[25]
|
Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkow-ski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S. and Larkin, J. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356. https://doi.org/10.1056/NEJMoa1709684
|
[26]
|
Dougan, M. (2017) Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Frontiers in Immunology, 8, Article No. 1547. https://doi.org/10.3389/fimmu.2017.01547
|
[27]
|
Gupta, A., De Felice, K.M., Loftus, E.V. and Khanna, S. (2015) Systematic Review: Colitis Associated with Anti-CTLA-4 Therapy. Alimentary Pharmacology & Therapeutics, 42, 406-417. https://doi.org/10.1111/apt.13281
|
[28]
|
Beck, K.E., Blansfield, J.A., Tran, K.Q., Feldman, A.L., Hughes, M.S., Royal, R.E., Kammula, U.S., Topalian, S.L., Sherry, R.M., Kleiner, D., Quezado, M., Lowy, I., Yellin, M., Ros-enberg, S.A. and Yang, J.C. (2006) Enterocolitis in Patients with Cancer after Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4. Journal of Clinical Oncology, 24, 2283-2289. https://doi.org/10.1200/JCO.2005.04.5716
|
[29]
|
Johnston, R.L., Lutzky, J., Chodhry, A. and Barkin, J.S. (2009) Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab. Digestive Diseases and Sciences, 54, 2538-2540.
https://doi.org/10.1007/s10620-008-0641-z
|
[30]
|
Nakahama, K., Tamiya, A., Taniguchi, Y., Sasaki, Y., Akira, M. and Atagi, S. (2017) Severe Acute Interstitial Lung Disease after Nivolumab in Three Non-Small Cell Lung Cancer Pa-tients with Imaging Findings of Airway Obstruction Adjacent to Lung Tumors. Journal of Infection and Chemotherapy, 23, 826-829.
https://doi.org/10.1016/j.jiac.2017.07.006
|
[31]
|
Naqash, A.R., Yang, L.V., Sanderlin, E.J., Atwell, D.C. and Walker, P.R. (2018) Interleukin-6 as One of the Potential Mediators of Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade: Evidence from a Case Report. Acta Oncologica, 57, 705-708.
https://doi.org/10.1080/0284186X.2017.1406668
|
[32]
|
Naidoo, J., Wang, X., Woo, K.M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J.E., Segal, N.H., Callahan, M.K., Lesokhin, A.M., Rosenberg, J., Voss, M.H., Rudin, C.M., Rizvi, H., Hou, X., Rodriguez, K., Albano, M., Gordon, R.A., Leduc, C., Rekhtman, N., Harris, B., Menzies, A.M., Guminski, A.D., Carlino, M.S., Kong, B.Y., Wolchok, J.D., Postow, M.A., Long, G.V. and Hellmann, M.D. (2017) Pneumonitis in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clini-cal Oncology, 35, 709-717.
https://doi.org/10.1200/JCO.2016.68.2005
|
[33]
|
Suresh, K., Naidoo, J., Lin, C.T. and Danoff, S. (2018) Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest, 154, 1416-1423. https://doi.org/10.1016/j.chest.2018.08.1048
|
[34]
|
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X. and Zhang, Y. (2018) The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients with Advanced Can-cer: A Meta-Analysis. Frontiers in Pharmacology, 9, Article No. 1430. https://doi.org/10.3389/fphar.2018.01430
|
[35]
|
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N.H. and Hodi, F.S. (2016) Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients with Advanced Can-cer: A Systematic Review and Meta-Analysis. JAMA Oncology, 2, 1607-1616. https://doi.org/10.1001/jamaoncol.2016.2453
|
[36]
|
Long, Y.X., Sun, Y., Liu, R.Z., Zhang, M.Y., Zhao, J., Wang, Y.Q., Zhou, Y.W., Cheng, K., Chen, Y., Zhu, C.R. and Liu, J.Y. (2022) Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). Current Oncology, 29, 267-282. https://doi.org/10.3390/curroncol29010025
|
[37]
|
Chen, X., Zhang, Z., Hou, X., Zhang, Y., Zhou, T., Liu, J., Lin, Z., Fang, W., Yang, Y., Ma, Y., Huang, Y., Zhao, H. and Zhang, L. (2020) Immune-Related Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: A Net-work Meta-Analysis. Journal for ImmunoTherapy of Cancer, 8, e001170. https://doi.org/10.1136/jitc-2020-001170
|
[38]
|
Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., He, J. and Liang, W. (2021) Immune-Related Adverse Events of a PD-L1 Inhibitor plus Chemotherapy versus a PD-L1 Inhibitor Alone in First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Control Trials. Cancer, 127, 777-786. https://doi.org/10.1002/cncr.33270
|
[39]
|
Borg, C., Ray-Coquard, I., Philip, I., Clapisson, G., Bendriss-Vermare, N., Menetrier-Caux, C., Sebban, C., Biron, P. and Blay, J.Y. (2004) CD4 Lymphopenia as a Risk Factor for Febrile Neutropenia and Early Death after Cytotoxic Chemotherapy in Adult Patients with Cancer. Cancer, 101, 2675-2680. https://doi.org/10.1002/cncr.20688
|
[40]
|
Shojaie, L., Ali, M., Iorga, A. and Dara, L. (2021) Mechanisms of Immune Checkpoint Inhibitor-Mediated Liver Injury. Acta Pharma-ceutica Sinica B, 11, 3727-3739. https://doi.org/10.1016/j.apsb.2021.10.003
|
[41]
|
Jennings, J.J., Mandaliya, R., Nakshabandi, A. and Lewis, J.H. (2019) Hepatotoxicity Induced by Immune Checkpoint Inhibitors: A Comprehensive Review Including Current and Alternative Management Strategies. Expert Opinion on Drug Metabolism & Toxicology, 15, 231-244. https://doi.org/10.1080/17425255.2019.1574744
|
[42]
|
Fu, J., Li, W.Z., McGrath, N.A., Lai, C.W., Brar, G., Xiang, Y.Q. and Xie, C. (2021) Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer versus Other Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, Article ID: 650292. https://doi.org/10.3389/fonc.2021.650292
|
[43]
|
Mitchell, J.R., Long, M.W., Thorgeirsson, U.P. and Jollow, D.J. (1975) Acetylation Rates and Monthly Liver Function Tests during One Year of Isoniazid Preventive Therapy. Chest, 68, 181-190. https://doi.org/10.1378/chest.68.2.181
|
[44]
|
Rossi, R.E., Parisi, I., Despott, E.J., Burroughs, A.K., O’Beirne, J., Conte, D., Hamilton, M.I. and Murray, C.D. (2014) Anti-Tumour Necrosis Factor Agent and Liver Injury: Literature Review, Recommendations for Management. World Journal of Gastroenterology, 20, 17352-17359. https://doi.org/10.3748/wjg.v20.i46.17352
|
[45]
|
Sullivan, R.J. and Weber, J.S. (2021) Immune-Related Toxicities of Checkpoint Inhibitors: Mechanisms and Mitigation Strategies. Nature Reviews Drug Discovery, 21, 495-508. https://doi.org/10.1038/s41573-021-00259-5
|
[46]
|
Sanchez, K., Page, D.B. and Urba, W. (2019) Immunotherapy Toxicities. Surgical Oncology Clinics of North America, 28, 387-401. https://doi.org/10.1016/j.soc.2019.02.009
|
[47]
|
Faje, A.T., Sullivan, R., Lawrence, D., Tritos, N.A., Fadden, R., Klibanski, A. and Nachtigall, L. (2014) Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients with Metastatic Melanoma. The Journal of Clinical Endocrinology & Metabolism, 99, 4078-4085. https://doi.org/10.1210/jc.2014-2306
|
[48]
|
Cukier, P., Santini, F.C., Scaranti, M. and Hoff, A.O. (2017) Endocrine Side Effects of Cancer Immunotherapy. Endocrine-Related Cancer, 24, T331-T347. https://doi.org/10.1530/ERC-17-0358
|